Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

AB238. Effect of Icariside II on miR-126 pathway on human cavernous endothelial cells exposed to a diabetic-like environment

Laboratory Study on Systemic / IV, published in Transl Androl Urol (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Transl Androl Urol (2016)
Reported sample size
—
Source database
Europe PMC
PMCID
PMC4842672

Abstract (original English)

Background To investigate the status of miR-126 and its targeting Spred1 under the stimulation of glucose and Age-BSA and to explore the effect of icariside II (ICA II) on the diabetic endothelial dysfunction of human cavernous endothelial cell (HCECs) by using the miR-126 pathway. Methods Purified HCECs were divided into three groups: normal group + BSA (NC group), Glucose + Age − BSA group (DM group), ICA II treatment group (DM + ICA II group). Western blot to detect the expression of eNOS, RAGE protein expression so as to make sure the success of model construction; immunofluorescence assay to study the proliferation of (HCECs); real time PCR to detect the expression of miR-126 and Spred1; western blot to detect the expression of the Spred1/c-Raf/MEK1/2/Erk1/2. Tube Formation Assay and Scratch assay were performed to detect the angiogenesis of HCECs under the diabetic-like environment. Results Under the model, the expression of eNOS in DM group significantly reduced compared with that of NC group and the expression of RAGE in DM group is significantly increased compared with that of NC group (P Conclusions Under the simulation of Age-BSA and glucose, HCECs occurred the endothelial dysfunction and the angiogenesis were repressed; ICA II could restore the HCECs functions by miR-126/Spred1/c-Raf/MEK1/2/Erk1/2 pathway. ICA II may be a promising therapeutic compound to treat endo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research